{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:57:39Z","timestamp":1719953859311},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1680,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.exphem.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T07:32:39Z","timestamp":1501227159000},"page":"71-75","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib"],"prefix":"10.1016","volume":"55","author":[{"given":"Bruno","family":"Martino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Mamm\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Labate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Ielo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Priolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Postorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"La Nasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2017.07.007_bib0010","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2017.07.007_bib0015","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2017.07.007_bib0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/13543784.2016.1142531","article-title":"Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes","volume":"25","author":"Malek","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.exphem.2017.07.007_bib0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/13543784.2013.802768","article-title":"Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes","volume":"22","author":"Prada","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.exphem.2017.07.007_bib0030","first-page":"168","article-title":"Incidence of hyperglycemia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ENESTnd","volume":"120","author":"Rea","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.07.007_bib0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2017.07.007_bib0040","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.V124.21.1813.1813","article-title":"Comparison of glucose and lipid metabolism abnormality during nilotinib, imatinib and dasatinib therapy: results of enigma 2 study","volume":"124","author":"Zdenek","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.07.007_bib0045","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db11-0415","article-title":"Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes","volume":"60","author":"Strawbridge","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.exphem.2017.07.007_bib0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/ng.2274","article-title":"A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance","volume":"44","author":"Manning","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2017.07.007_bib0055","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.2337\/db13-0949","article-title":"Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity","volume":"63","author":"Dimas","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.exphem.2017.07.007_bib0060","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.2337\/db14-0319","article-title":"Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity","volume":"63","author":"Scott","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.exphem.2017.07.007_bib0065","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.07.007_bib0070","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.exphem.2017.07.007_bib0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0168-8227(99)00116-3","article-title":"Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures","volume":"47","author":"Gutt","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"issue":"suppl","key":"10.1016\/j.exphem.2017.07.007_bib0080","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"Classification and diagnosis of diabetes","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.exphem.2017.07.007_bib0085","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.07.007_bib0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","article-title":"Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase","volume":"118","author":"Nicolini","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2017.07.007_bib0095","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.07.007_bib0100","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3324\/haematol.2016.144949","article-title":"Nilotinib 300\u2009mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients","volume":"101","author":"Castagnetti","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2017.07.007_bib0105","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.leukres.2011.12.011","article-title":"Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2017.07.007_bib0110","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2017.07.007_bib0115","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V116.21.3430.3430","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.07.007_bib0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2337\/db08-0080","article-title":"Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db\/db mice","volume":"58","author":"Han","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.exphem.2017.07.007_bib0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1042\/CS20070122","article-title":"Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet","volume":"114","author":"H\u00e4gerkvist","year":"2008","journal-title":"Clin Sci"},{"key":"10.1016\/j.exphem.2017.07.007_bib0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature01137","article-title":"A central role for JNK in obesity and insulin resistance","volume":"420","author":"Hirosumi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2017.07.007_bib0135","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2017.07.007_bib0140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1365-2141.2001.02428.x","article-title":"Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model","volume":"112","author":"Bentley","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2017.07.007_bib0145","author":"Nicolucci"},{"key":"10.1016\/j.exphem.2017.07.007_bib0150","doi-asserted-by":"crossref","first-page":"e1001230","DOI":"10.1371\/journal.pmed.1001230","article-title":"Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. InterAct Consortium","volume":"9","author":"Langenberg","year":"2012","journal-title":"PLoS Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1730663X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1730663X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:30:26Z","timestamp":1654925426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1730663X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":29,"alternative-id":["S0301472X1730663X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2017.07.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}